Loading clinical trials...
Loading clinical trials...
A Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Conditions
Interventions
young TIL
Pembrolizumab
+3 more
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
December 4, 2015
Primary Completion Date
June 16, 2028
Completion Date
June 16, 2029
Last Updated
April 24, 2026
NCT07177937
NCT03050268
NCT05969860
NCT03340506
NCT04693377
NCT04895709
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions